Super-enhancer-driven ZFP36L1 promotes PD-L1 expression in infiltrative gastric cancer
eLife · 07.10.2024 · 13
DOI: 10.7554/elife.96445 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, online erschienen am 07.10.2024. Verfasst von Xujin Wei und 9 weiteren Autor:innen. Beteiligte Einrichtung: Endoscopic Center, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, B7-H1 Antigen, Butyrate Response Factor 1, Gene Expression Regulation, Neoplastic. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Fujian Province.
Abstract (Originalsprache)
Gastric cancer (GC) is a major cause of cancer-related mortality worldwide. Despite the widespread recognition of tumor immunotherapy in treating unresectable GC, challenges, including ineffective immunotherapy and drug resistance, persist. Therefore, understanding the regulatory mechanisms of PD-L1, particularly in the context of super-enhancers (SEs) and zinc finger protein 36 ring finger protein-like 1 (ZFP36L1) RNA-binding protein, is crucial. In this study, we performed H3K27ac Cleavage Under Targets and Tagmentation (CUT&Tag) sequencing, investigated the heterogeneity of SEs between two GC subtypes with differential growth patterns, and revealed the immune escape signatures driven by ZFP36L1-SE in infiltrative GC through SEs inhibitors treatment. The regulation of ZFP36L1 to PD-L1 was evaluated by quantitative PCR, western blot, flow cytometry, and immunohistochemistry. Furthermore, we explored its regulatory mechanisms using a combination of molecular biology techniques, including luciferase reporter assay, GST/RNA pull-down, chromatin immunoprecipitation (ChIP)/RIP experiments, and in vivo functional assays. We demonstrated that ZFP36L1, driven by an SE, enhances IFN-γ-induced PD-L1 expression, with SPI1 identified as the specific transcription factor binding to ZFP36L1-SE. Mechanistically, ZFP36L1 binds to the adenylate uridylate-rich element in the 3ʹ untranslated region (3ʹUTR) of HDAC3 mRNA, exacerbating its mRNA decay, and thereby facilitating PD-L1 abnormal transcriptional activation. Collectively, our findings provide mechanistic insights into the role of the SPI1-ZFP36L1-HDAC3-PD-L1 signaling axis in orchestrating immune escape mechanisms in GC, thereby offering valuable insights into the potential targets for immune checkpoint therapy in GC management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endoscopic Center, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
- The Graduate School of Fujian Medical University, Fuzhou, China.
- Department of Gastrointestinal Surgery, Zhongshan Hospital of Xiamen University, Institute of Gastrointestinal Oncology, School of Medicine, Xiamen University, Xiamen, China.
- Xiamen Municipal Key Laboratory of Gastrointestinal Oncology, Xiamen, China.
ORCID-Profile: Xujin Wei, Jie Liu, Jia Cheng, Jianchun Cai, Huiqin Zhuo
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Fujian Province
Zitieren
APA
Wei, X., Liu, J., Cheng, J., Cai, W., Xie, W., Wang, K., Lin, L., Hou, J., Cai, J., & Zhuo, H. (2024). Super-enhancer-driven ZFP36L1 promotes PD-L1 expression in infiltrative gastric cancer. eLife, 13. https://doi.org/10.7554/elife.96445
Vancouver
Wei X, Liu J, Cheng J, Cai W, Xie W, Wang K, et al. Super-enhancer-driven ZFP36L1 promotes PD-L1 expression in infiltrative gastric cancer. eLife. 2024;13. doi:10.7554/elife.96445
BibTeX
@article{Wei2024,
author = {Wei, Xujin and Liu, Jie and Cheng, Jia and Cai, Wangyu and Xie, Wen and Wang, Kang and Lin, Lingyun and Hou, Jingjing and Cai, Jianchun and Zhuo, Huiqin},
title = {Super-enhancer-driven ZFP36L1 promotes PD-L1 expression in infiltrative gastric cancer},
journal = {eLife},
year = {2024},
volume = {13},
doi = {10.7554/elife.96445}
}
EUVIMED